WO2003035910A1 - Transfection kinetics and structural promoters - Google Patents
Transfection kinetics and structural promoters Download PDFInfo
- Publication number
- WO2003035910A1 WO2003035910A1 PCT/US2002/033669 US0233669W WO03035910A1 WO 2003035910 A1 WO2003035910 A1 WO 2003035910A1 US 0233669 W US0233669 W US 0233669W WO 03035910 A1 WO03035910 A1 WO 03035910A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dna
- expression
- transfection
- protein
- promoter
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
Definitions
- This invention provides methods for quantifying and describing the kinetics of transfection. Also provided is a method for creating permanent and transient forced-open complexes in supercoiled DNA, which function as strong transcriptional promoters.
- the effect of any expression element on transfection is measured by (i) transfecting a host cell with several sub-saturating concentrations of a vector comprising the expression element; (ii) measuring the activity of a reporter protein; (iii) measuring the expression of the same reporter protein under the same transfection conditions transfected into identical host cells using a vector that is deficient in the expression element under study; and (iv) comparing the expression levels using an inverse plot transformation.
- the invention provides a method of expressing a protein consisting of the steps of (i) annealing to a supercoiled DNA, an oligonucleotide that is complimentary to a DNA sequence upstream from the protein coding sequence; (ii) transfecting the resulting supercoiled DNA into a host cell; (iii)culturing the host cell under conditions that promote expression of the protein.
- the supercoiled DNA is an expression vector.
- Preferred expression vectors contain a transcriptional promoter operably linked to a protein coding sequence.
- the oligonucleotide forms a heteroduplex with the supercoiled DNA.
- the oligonucleotide is complimentary to a naturally occurring or artificially inserted promoter sequence.
- the oligonucleotide consists of at least 10 nucleotides, preferably at least 20 nucleotides, more preferably at least 30 nucleotides, most preferably at least 40 nucleotides, or even at least 50 nucleotides.
- the invention provides a method of expressing a protein consisting of the steps of (i) annealing a linear single stranded DNA to the supercoiled DNA; (ii) ligating the 3' end of the linear DNA to the 5' end; (iii) transfecting the resulting supercoiled DNA into a host cell; and (iv) culturing the host cell under conditions that promote expression of the protein.
- each of the 3' end and the 5' end of the linear DNA is complimentary to at least 5 nucleotides of the supercoiled DNA, more preferably, each is complimentary to at least 10 nucleotides, even more preferably at least 15 nucleotides, most preferably at least 20 nucleotides, or even 30 nucleotides.
- the regions of complimentarity are continuous and are contained within a promoter region.
- expression element is meant any feature or sequence of a DNA molecule that affects transcription or translation of a nucleic acid sequence.
- Example of expression elements include promoters, enhancers, repressors, and introns. Expression elements that can be assessed using this invention also include protein elements such as transcriptional or translational enzymes, for example, polymerases and transcription factors.
- commitment to expression is meant the likelihood of transcriptional initiation.
- the commitment to expression is quantified numerically by the K m .
- operably linked is meant that a nucleic acid molecule and one or more regulatory sequences (e.g., a promoter) are connected in such a way as to permit expression and/or secretion of the product (i.e., a polypeptide) of the nucleic acid molecule when the appropriate molecules are bound to the regulatory sequences.
- a regulatory sequence e.g., a promoter
- promoter a nucleic acid sequence sufficient to direct transcription of a covalently linked nucleic acid molecule.
- Figure 1 is a graph of reporter gene expression as a function of the plasmid DNA concentration used in the transfection procedure.
- Figure 2 is a series of graphs showing the ⁇ -gal enzymatic activity and mRNA levels in RD cells following transfection with varying amounts vector DNA.
- Figure 3 is a series of graphs showing that the transfection process is amenable to steady state kinetic analysis.
- Figure 4 is a series of graphs comparing ⁇ -gal activity following transfection under sub-saturating conditions in RD cells, ⁇ -gal is under the control of either the HCMV, SCMN, or HCMNm promoter.
- Figure 5 is a graph comparing the ⁇ -gal activity in RD cells following transfection with vectors containing either an HCMN or SCMN promoter. Single construct transfections are compared to mixed transfections.
- Figure 6 is a graph comparing the effects of inclusion or deletion of the enhancer element of Ef ⁇ promoter.
- Figure 7 is a graph comparing the effects of the HCMN and Pmin promoters on ⁇ -gal expression in RD cells after transfection using sub- saturating conditions.
- Figure 8 is a graph comparing the effects of the HCMN and RSN promoters on ⁇ -gal expression in RD cells after transfection using sub- saturating conditions.
- Figure 9 is a schematic of open complex formation under normal and forced conditions.
- Figure 10 is a schematic showing the natural "breathing" of supercoiled
- Figure 11 is a schematic demonstrating the molecular mechanism for heteroduplex formation in a D ⁇ A supercoil.
- Figure 12 is a schematic showing the strategy used for designing oligonucleotides useful for heteroduplex formation.
- Figure 13 is a graph showing the ⁇ -gal activity in RD cells, transfected under sub-saturating conditions, where the vector was incubated with a synthetic oligonucleotide prior to transfection.
- Figure 14 is a graph comparing the ⁇ -gal activity in RD cells, transfected under sub-saturating conditions, where the vector was incubated with synthetic oligonucleotides of varying lengths and specificities.
- Figure 15 depicts an electrophoretic separation of vector DNA following incubation and enzymatic ligation with a 32 P-labeled "padlock" oligonucleotide.
- the left figure is a photograph of the gel stained with ethidium bromide.
- the right figure is an autoradiogram of the same gel.
- Transfection of DNA into cells is the primary step in the analysis of gene expression. Quantitative analysis of gene expression requires that transfection efficiency differences do not compromise the comparative analysis of expression elements.
- the present invention relates to methods for analyzing the relative expression of transfection constructs. The methods are based on our discovery that transfection is a saturable process, and that the expression profile of a reporter construct is amenable to steady state kinetic analysis.
- the expression of various genetic elements can be described using the standard kinetic constants, N max and m .
- the K m is a measure of the commitment to expression of a genetic element.
- the N max is a measure of the relative expression potential of the element, at infinite (unlimited) concentrations of template D ⁇ A. K m and V max do not co-segregate with the same D ⁇ A sequences. Therefore, it is possible to create artifical promoters using elements of low K m and high N max .
- Transfections were performed using cationic lipid (Lipofectamine) complexed D ⁇ A in human Rhabdomyosarcoma (RD) cells. Amounts of transfected reporter gene plasmid in transfection mixes ranged from 50 ng to 2.5 ⁇ g/transfection. The total amount of DNA per transfection was held constant at 2.5 ⁇ g by adding a promoterless control plasmid to each transfection reaction.
- Lipofectamine cationic lipid
- RD Rhabdomyosarcoma
- Plasmids were designed to express ⁇ -galactosidase or human secreted alkaline phosphatase (SEAP), and contained various promoter elements including the HCMN, SCMN, HCMVm(gfi), and elongation factor alpha (minimal and complete) promoters. Additionally, intron-containing and intronless vectors were compared.
- SEAP human secreted alkaline phosphatase
- Beta-galactosidase ( ⁇ -gal) activity was measured in the lysates of transfected cells using a colorimetric kinetic enzyme assay, and normalized to total cellular protein. SEAP activity was measured in the media of transfected cells. Expression is plotted as the initial velocity of the reaction for each D ⁇ A concentration tested. The initial velocity of the enzymatic reactions is directly proportional to the amount of the enzyme present.
- Enzymatic assays were performed at 1, 2, and 4 days post-transfection. All vectors, regardless of cell type, resulted in transfection saturation. Saturation occurred at expression vector levels ranging from 200 ng - 1 ⁇ g per 6-7x10 5 cells. Saturation varied depending upon the specific vector construct and the time point after transfection analyzed.
- RNA Analysis Total R ⁇ A was isolated from cells using the StrataPrep Total R ⁇ A Miniprep Kit (Stratagene). Three micrograms of total R ⁇ A was run on a 1.2% agarose- formaldehyde gel, transferred to Zeta-probe membrane (Bio- Rad), and probed with ⁇ -gal sequences. After initial hybridization, the membrane was stripped and probed for actin R ⁇ A. Probes were 32 P-labeled using random primed synthesis. The resulting signals were visualized and quantitated by phosphorimage analysis. Relative R ⁇ A values were obtained by normalizing ⁇ -gal R ⁇ A to actin R ⁇ A.
- Figure 2 shows representative results of ⁇ -gal enzymatic activity and mRNA level, as a function of vector DNA concentration. Experiments were performed in duplicate, ⁇ -gal expression was found to be linear up to 1 ⁇ g of transfected reporter plasmid, after which, expression levels became saturated, ⁇ -gal RNA levels were linear over the entire range of DNA concentration used. Replicates exhibited less than 5% variation. Together, these data show that saturation occurs at a post-transcriptional step.
- ⁇ -gal reporter plasmid 200 ng
- a super-saturating amount of a second plasmid 2.3 ⁇ g
- the second plasmid was either HCMN-HSNgD (expresses a protein product), HCMNOHPNLl (expresses mR ⁇ A that is transcribed, transported to the cytoplasm, but not translated), or pLUC (promoterless plasmid that is not transcribed).
- ⁇ -gal protein and mR ⁇ A were measured and normalized as previously described. The lowest expression of protein and R ⁇ A was assigned an arbitrary value of one, and the ratio of ⁇ -gal protein:R ⁇ A was compared.
- mR ⁇ A Approximately equal amounts of mR ⁇ A are made by the HCMN- HSVgD and the HCMN-HPNL1 plasmids, as measured by RT-PCR. There was no difference in the amount of ⁇ -gal protein per unit ⁇ -gal R ⁇ A in cells co- transfected with non-protein coding plasmids compared to cells transfected without a competing plasmid. However, cells co-transfected with plasmids that directed the synthesis of a protein, 14-18 fold less ⁇ -gal protein per unit ⁇ -gal R ⁇ A was produced (compare pLUC or HCMV-HPNL1 to HCMN-HSNgD). These results further demonstrate that saturation occurs post-translationally.
- Figure 4 is an inverse plot of initial velocities as a function of DNA concentration.
- the N ma ⁇ is derived from the Y-axis intercept, and the K m from the X-axis intercept.
- the HCMN promoter when compared with the SCMN promoter, demonstrates differences in initial velocity rates. Therefore, even at saturating substrate concentrations, these two promoters are predicted to have different levels of activity (HCMN>SCMN).
- the similarity of K m values suggests similar commitments to catalysis.
- the two promoters When the HCMN promoter is compared with the HCMNm version, harboring a mutation in the gfi box (transcriptional repressor site), the two promoters have significant differences in their initial velocity rates, but at saturating concentrations of D ⁇ A, they are predicted to have similar velocities (N max )- The promoters do, however, have different K m values, with the mutant showing a higher commitment to catalysis (lower K m ). K m differences reflect differences in events that lead to transcription initiation resulting from differences in affinity for the transcription machinery. N max differences reflect, in most instances, the activity following transfection with infinite D ⁇ A concentrations.
- RD cells were transfected with the HCMV ⁇ -gal reporter plasmid, the SCMN ⁇ -gal reporter plasmid, or a mixture of the two plasmids (H+SCMN).
- reporter plasmid D ⁇ A amounts were 50 - 400 ng. Total D ⁇ A per transfection was held constant at 2.5 ⁇ g by adding a promoterless control plasmid.
- H+SCMN mixed plasmid transfection
- equal amounts of each plasmid were used (e.g. the 50 ng transfection contained 25 ng of each plasmid).
- the relative expression level of HCMN to SCMV (2.022) is derived from the ratio of the slopes (1.998 ⁇ 0.988). The differences, however, may reflect variations in transfection efficiencies rather than true differences in relative expression levels. Variations in transfection efficiency were measured in a mixed transfection.
- Figure 6 shows the effect of the enhancer element on the elongation factor alpha promoter Ef ⁇ P, where Pe is the minimal EF promoter, the native enhancer and the coding sequence.
- the Px construct consists of the minimal EF promoter and the coding region; the native enhancer is deleted.
- the inverse plot demonstrates that the enhancer element reduces the promoter's commitment to transcription (increases K m ), but increases the maximal rate at which the gene will be transcribed (increases
- Figure 7 compares the kinetics of the HCMV promoter with the Ef ⁇ IP without the enhancer (Pmin).
- the inverse plot demonstrates that the HCMV promoter has a relatively strong commitment to transcription. Therefore, the HCMV promoter would be expected to be active at a low copy number, and is useful under sub-saturating transfection conditions.
- Figure 8 compares the kinetics of the HCMV promoter to the Raus
- Sarcoma virus promoter (RSV). Both promoters are approximately equally committed to transcription; however, the HCMV promoter will result in higher expression levels at any concentration of transfection DNA.
- sequence elements that contribute to K m and V max effects can be mapped by random mutation either in vitro (PCR based, sequence shuffling, mutagenizing), or in vivo in bacteria or eukaryotic cells with single or multiple copy plasmids, or integrated sequences (retroviruses, random integration, Cre- Lox). Once identified, the sequence elements can be spliced together to get the desired promoter effect, such as a promoter with a low K m and a high V max .
- Example 3 Forced Open Promoter Complex
- the function of a promoter is to affect transcriptional initiation, the rate- limiting step in transcription.
- the traditional approach to improving promoter functionality has been through the identification and optimization of nucleic acid sequences with desirable properties which result in high level transcription initiation. To date, attempts to create an unregulated promoter have been unsuccessful.
- the rate of transcription initiation is limited by open complex formation (melting of the transcriptional start site), and is dependent on the promoter sequence and the transcription factors that bind the promoter sequences (Figure 9).
- a bubble of unbasepaired DNA resembles the transcription bubble associated with open promoter complexes. Transcription from these bubbles is stimulated in excess of a hundred- fold relative to the completely duplexed promoter elements, suggesting that blocking complete base pairing within a promoter sequence can generate open promoter complexes.
- Supercoiled DNA throws out single stranded DNA loops in order to release torsional stress. Loop formation is random and dynamic (Figure 10).
- oligonucleotide concentrations are high relative to plasmid concentrations, the loops will anneal to complementary oligonucleotides instead of the partner plasmid strand. This creates a heteroduplex.
- potassium permanganate probing reveals that the regions of plasmid DNA on either side of the annealed oligonucleotide are not basepaired with the partner plasmid DNA strand. This basepairing is presumably thermodynamically unfavorable.
- the heteroduplex between the oligonucleotide and the supercoiled vector, creating a free single strand in the vector creates on open promoter complex which favors transcriptional initiation.
- heteroduplex An unregulated, or "super promoter,” would be formed if the heteroduplex is stabilized for an indefinite period of time.
- stabilization is enhanced by creating a heteroduplex "padlock" on the promoter sequence.
- DNA padlocking is done by incubating supercoiled plasmids with a relatively high concentration (1000 fold molar excess) of a linear DNA (padlock) containing a 5' end that is complementary to the 3' end of the target sequence, and a 3' end that is complementary to the 5' end of the target sequence.
- the regions of complimentarity of the 5' and 3' end of the DNA must be contiguous and should be at least ten nucleotides in length.
- the intervening, connector sequence can be random sequence that is not complementary to any portion of the vector, or can be sequence useful for targeting or transcriptional purposes. Examples of useful, non-random sequence include sequences that promote RNA polymerase binding.
- the padlock DNA is ligated by chemical or enzymatic means ( Figure 11). Ligation of the 5' and 3' ends of the padlock DNA forms a "knotted" structure, where the padlock DNA is wrapped around the vector DNA once for about every ten nucleotides. The resulting heteroduplex is, therefore, stabilized indefinitely, forming a permanent forced-open complex and should be unaffected by transcriptional repressors, or a lack of transcriptional enhancers.
- a permanent forced-open complex can be formed at any DNA sequence, and acts to promote transcription of the downstream sequence.
- SCI 001 is a 38-mer which overlap the CAT and TATA boxes of the HCMV- ⁇ - gal plasmid.
- SCI 002 is a 45-mer, containing SCI 001, but extending towards the +1 site.
- SC1003 is a scrambled 45-mer with the same nucleotide composition as SCI 002, but without complimentarity to any region of the plasmid.
- Figure 14 shows that, following incubation with the vector (oligonucleotides at 1000 fold molar excess), both of the complimentary oligonucleotides function as strong promoters with very low K m values. No significant difference was observed in the V max .
- the forced open complex has a Km value at least several hundred fold less than the native HCMV promoter, suggesting that this construct will be active at only a few, or even a single copy per cell.
- Figure 15 is a photograph of the agarose gel stained with ethidium bromide, showing the presence of all three forms of DNA (supercoiled, nicked, and linear). Also included is an autoradiogram of the same gel showing that the only supercoiled DNA is capable of being padlocked. Additionally, the padlock did not bind to the control plasmid.
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Lubricants (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Oscillators With Electromechanical Resonators (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK02782194T DK1444363T3 (en) | 2001-10-22 | 2002-10-22 | Transfection kinetics and structural promoters |
CA002464464A CA2464464A1 (en) | 2001-10-22 | 2002-10-22 | Transfection kinetics and structural promoters |
EP02782194A EP1444363B1 (en) | 2001-10-22 | 2002-10-22 | Transfection kinetics and structural promoters |
DE60214877T DE60214877T2 (en) | 2001-10-22 | 2002-10-22 | TRANSFECTION KINETICS AND STRUCTURAL PROMOTERS |
AU2002348372A AU2002348372B2 (en) | 2001-10-22 | 2002-10-22 | Transfection kinetics and structural promoters |
US10/829,747 US7527945B2 (en) | 2001-10-22 | 2004-04-22 | Transfection kinetics and structural promoters |
US12/034,541 US7897382B2 (en) | 2001-10-22 | 2008-02-20 | Transfection kinetics and structural promoters |
US13/022,833 US20110223634A1 (en) | 2001-10-22 | 2011-02-08 | Transfection kinetics and structural promoters |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34278801P | 2001-10-22 | 2001-10-22 | |
US60/342,788 | 2001-10-22 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/829,747 Continuation-In-Part US7527945B2 (en) | 2001-10-22 | 2004-04-22 | Transfection kinetics and structural promoters |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003035910A1 true WO2003035910A1 (en) | 2003-05-01 |
WO2003035910A9 WO2003035910A9 (en) | 2004-12-23 |
Family
ID=23343276
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2002/033669 WO2003035910A1 (en) | 2001-10-22 | 2002-10-22 | Transfection kinetics and structural promoters |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1444363B1 (en) |
AT (1) | ATE340271T1 (en) |
AU (2) | AU2002348372B2 (en) |
CA (1) | CA2464464A1 (en) |
DE (1) | DE60214877T2 (en) |
DK (1) | DK1444363T3 (en) |
WO (1) | WO2003035910A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1623009A2 (en) * | 2003-04-22 | 2006-02-08 | Nucleonics, Inc | Transfection kinetics and structural promoters |
WO2006036872A2 (en) | 2004-09-24 | 2006-04-06 | Nucleonics, Inc. | Targeting opposite strand replication intermediates of single-stranded viruses by rnai |
US7897382B2 (en) | 2001-10-22 | 2011-03-01 | Alnylam Pharmaceuticals, Inc. | Transfection kinetics and structural promoters |
US20120003265A1 (en) * | 2004-06-17 | 2012-01-05 | Wyeth Llc | Immunogenic compositions for inducing an immune response to hiv |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5849727A (en) * | 1996-06-28 | 1998-12-15 | Board Of Regents Of The University Of Nebraska | Compositions and methods for altering the biodistribution of biological agents |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE9400522D0 (en) * | 1994-02-16 | 1994-02-16 | Ulf Landegren | Method and reagent for detecting specific nucleotide sequences |
-
2002
- 2002-10-22 WO PCT/US2002/033669 patent/WO2003035910A1/en active IP Right Grant
- 2002-10-22 AT AT02782194T patent/ATE340271T1/en active
- 2002-10-22 CA CA002464464A patent/CA2464464A1/en not_active Abandoned
- 2002-10-22 DE DE60214877T patent/DE60214877T2/en not_active Expired - Lifetime
- 2002-10-22 AU AU2002348372A patent/AU2002348372B2/en not_active Ceased
- 2002-10-22 EP EP02782194A patent/EP1444363B1/en not_active Expired - Lifetime
- 2002-10-22 DK DK02782194T patent/DK1444363T3/en active
-
2008
- 2008-11-25 AU AU2008249197A patent/AU2008249197B2/en not_active Ceased
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5849727A (en) * | 1996-06-28 | 1998-12-15 | Board Of Regents Of The University Of Nebraska | Compositions and methods for altering the biodistribution of biological agents |
Non-Patent Citations (1)
Title |
---|
STRYER L.: "Chapter 8 Introduction to enzymes", 1988, BIOCHEMISTRY, THIRD EDITION, pages: 189, XP002961206 * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7527945B2 (en) | 2001-10-22 | 2009-05-05 | Nucleonics, Inc. | Transfection kinetics and structural promoters |
US7897382B2 (en) | 2001-10-22 | 2011-03-01 | Alnylam Pharmaceuticals, Inc. | Transfection kinetics and structural promoters |
EP1623009A2 (en) * | 2003-04-22 | 2006-02-08 | Nucleonics, Inc | Transfection kinetics and structural promoters |
EP1623009A4 (en) * | 2003-04-22 | 2008-02-13 | Nucleonics Inc | Transfection kinetics and structural promoters |
US20120003265A1 (en) * | 2004-06-17 | 2012-01-05 | Wyeth Llc | Immunogenic compositions for inducing an immune response to hiv |
US8623382B2 (en) | 2004-06-17 | 2014-01-07 | Wyeth Llc | Immunogenic compositions for inducing an immune response to HIV |
WO2006036872A2 (en) | 2004-09-24 | 2006-04-06 | Nucleonics, Inc. | Targeting opposite strand replication intermediates of single-stranded viruses by rnai |
EP2325314A2 (en) | 2004-09-24 | 2011-05-25 | Alnylam Pharmaceuticals, Inc. | Targeting opposite strand replication intermediates of single-stranded viruses by RNAI |
Also Published As
Publication number | Publication date |
---|---|
EP1444363A4 (en) | 2004-12-15 |
AU2002348372B2 (en) | 2008-08-28 |
DE60214877D1 (en) | 2006-11-02 |
DE60214877T2 (en) | 2007-02-15 |
ATE340271T1 (en) | 2006-10-15 |
EP1444363B1 (en) | 2006-09-20 |
WO2003035910A9 (en) | 2004-12-23 |
EP1444363A1 (en) | 2004-08-11 |
AU2008249197A1 (en) | 2008-12-18 |
DK1444363T3 (en) | 2007-01-29 |
AU2002348372A2 (en) | 2003-05-06 |
CA2464464A1 (en) | 2003-05-01 |
AU2008249197B2 (en) | 2012-01-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9493768B2 (en) | Translational enhancer-element dependent vector systems | |
Elmendorf et al. | Initiator and upstream elements in the α2-tubulin promoter of Giardia lamblia | |
Mangin et al. | Human U2 small nuclear RNA genes contain an upstream enhancer. | |
Eszterhas et al. | Transcriptional interference by independently regulated genes occurs in any relative arrangement of the genes and is influenced by chromosomal integration position | |
EP2668277B1 (en) | Method for the construction of specific promoters | |
US6027915A (en) | Expression augmenting sequence elements (EASE) for eukaryotic expression systems | |
US8680256B2 (en) | Methods for producing inducible and/or repressible expression active linear RNA interference cassettes and inducible and/or repressible expression active linear gene cassettes and their uses | |
Yan et al. | Tetracycline regulated gene expression in Leishmania donovani | |
AU2008249197B2 (en) | Transfection kinetics and structural promoters | |
AU2002348372A1 (en) | Transfection kinetics and structural promoters | |
Sepulveda et al. | The mouse gamma-glutamyl transpeptidase gene is transcribed from at least five separate promoters. | |
US7527945B2 (en) | Transfection kinetics and structural promoters | |
US6596514B2 (en) | Expression augmenting sequence elements (EASE) for eukaryotic expression systems | |
Huang et al. | RNA processing in the polyoma virus life cycle | |
US7897382B2 (en) | Transfection kinetics and structural promoters | |
EP2307567B1 (en) | Methods for producing inducible and/or repressible expression active linear rna interference cassettes and inducible and/or repressible expression active linear gene cassettes and their uses | |
Lu et al. | Molecular cloning and characterization of the promoter of mouse heme-regulated eIF2α kinase | |
US7504492B2 (en) | RNA polymerase III promoter, process for producing the same and method of using the same | |
Maniak et al. | 3′ processing in Dictyostelium: unusual sequence requirements and interaction with a downstream promoter | |
Torkzaban et al. | Tethered mRNA Amplifier: A Novel Approach to Increase Protein Expression | |
Lu et al. | The Extragenic Spacer Length Between the 5 [variant prime] and 3 [variant prime] Ends of the Transgene Expression Cassette Affects Transgene Silencing From Plasmid-based Vectors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2464464 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002348372 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002782194 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2002782194 Country of ref document: EP |
|
COP | Corrected version of pamphlet |
Free format text: PAGES 1/15-15/15, DRAWINGS, REPLACED BY NEW PAGES 1/16-16/16; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |
|
WWG | Wipo information: grant in national office |
Ref document number: 2002782194 Country of ref document: EP |